[1]胡伟雄.心血管内科住院患者抗高血压药物用药合理性调查[J].医学信息,2021,34(11):9-11.[doi:10.3969/j.issn.1006-1959.2021.11.003]
　HU Wei-xiong.Investigation on the Rationality of Antihypertensive Drugs in Hospitalized Patients of Cardiovascular Medicine[J].Medical Information,2021,34(11):9-11.[doi:10.3969/j.issn.1006-1959.2021.11.003]
点击复制

心血管内科住院患者抗高血压药物用药合理性调查()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年11期
页码:
9-11
栏目:
出版日期:
2021-06-01

文章信息/Info

Title:
Investigation on the Rationality of Antihypertensive Drugs in Hospitalized Patients of Cardiovascular Medicine
文章编号:
1006-1959（2021）11-0009-03
作者:
胡伟雄
（惠来县人民医院药剂科，广东 惠来 515200）
Author(s):
HU Wei-xiong
(Department of Pharmacy,Huilai County People’s Hospital,Huilai 515200,Guangdong,China)
关键词:
心血管内科; 高血压; 抗高血压药物; 合理用药
Keywords:
Cardiovascular medicine; Hypertension; Antihypertensive drugs; Rational use of drugs
分类号:
R544.1；R972.4
DOI:
10.3969/j.issn.1006-1959.2021.11.003
文献标志码:
A
摘要:
目的 分析心血管内科住院患者抗高血压药物的用药合理性。方法 收集我院2019年12月~2020年12月428例高血压住院患者的临床资料，分析其抗高血压药物的用药合理性。结果 抗高血压药物中，钙通道阻滞剂（CCB）使用频率最高，其次分别为β受体阻滞剂（β-RB）、利尿剂、血管紧张素转换酶抑制剂（ACEI）、血管紧张素Ⅱ受体阻滞剂（ARB）以及复方制剂；使用频率最高的抗高血压药物为硝苯地平控释片，其次分别为酒石酸美托洛尔缓释片、马来酸依那普利片、氢氯噻嗪片以及缬沙坦胶囊。DDDs值最高的药物为硝苯地平控释片，其次分别为酒石酸美托洛尔缓释片、马来酸依那普利片、氢氯噻嗪片以及缬沙坦胶囊。其中硝苯地平控释片DUI为0.98，酒石酸美托洛尔缓释片DUI为0.93，马来酸依那普利片DUI为1.02，氢氯噻嗪片DUI为0.97，缬沙坦胶囊DUI为0.90。单一用药58例，二联用药181例，三联用药143例，四联用药40例，五联用药4例，六联用药2例。CCB联合β-RB联用方法最多（15.65%）；其次分别为CCB联合ACEI（12.62%）、CCB联合β-RB以及利尿剂（10.98%）、利尿剂联合ACEI（7.01%）、ACEI联合β-RB以及利尿剂（6.78%）。结论 我院抗高血压药物的应用整体较为科学，但仍存在一定的不合理现象，如药物选择不当、重复用药、药物联用不当、用药方法不当等。临床应根据高血压患者的疾病情况以及药物特点，保证用药的合理性，遵循个性化治疗原则，从而达到理想的疗效，改善患者预后。
Abstract:
Objective To analyze the rationality of antihypertensive drugs for inpatients in the Department of Cardiology.Methods The clinical data of 428 inpatients with hypertension in our hospital from December 2019 to December 2020 were collected, and the rationality of their antihypertensive drugs was analyzed.Results Among the antihypertensive drugs, calcium channel blockers (CCB) were used most frequently.Next were β-receptor blockers (β-RB), diuretics, angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) and compound preparations;The most frequently used antihypertensive drugs were nifedipine controlled-release tablets, followed by metoprolol tartrate sustained-release tablets, enalapril maleate tablets, hydrochlorothiazide tablets, and valsartan capsules.The drug with the highest DDDs value was nifedipine controlled-release tablets, followed by metoprolol tartrate sustained-release tablets, enalapril maleate tablets, hydrochlorothiazide tablets and valsartan capsules.Among them, the DUI of nifedipine controlled-release tablets was 0.98, the DUI of metoprolol tartrate sustained-release tablets was 0.93, the DUI of enalapril maleate tablets was 1.02, the DUI of hydrochlorothiazide tablets was 0.97, and the DUI of valsartan capsules was 0.90.There were 58 cases of single medication, 181 cases of double combination, 143 cases of triple combination, 40 cases of quadruple combination, 4 cases of five combination, and 2 cases of six combination.CCB combined with β-RB had the most combined methods (15.65%); followed by CCB combined with ACEI (12.62%), CCB combined with β-RB and diuretics (10.98%), diuretics combined with ACEI (7.01%), ACEI combined with β-RB and diuretics (6.78%).Conclusion The overall application of antihypertensive drugs in our hospital is relatively scientific, but there are still certain unreasonable phenomena, such as improper drug selection, repeated medication, improper combination of drugs, improper medication methods, etc.The clinic should ensure the rationality of the medication according to the disease situation and the characteristics of the drugs in patients with hypertension, and follow the principles of individualized treatment, so as to achieve the desired curative effect and improve the prognosis of the patients.

参考文献/References:

[1]赵枫.高血压性脑出血患者术后药物治疗中辅助药物应用的合理性[J].上海医药,2020,41(13):23-24,32. [2]Juric D,Pavlicevic I,Marusic A,et al.Effectiveness of treatment of newly diagnosed hypertension in family medicine practices in South Croatia[J].BMC family practice,2019,20(1):10. [3]鲍志伟.心内科老年高血压患者抗高血压药物用药的合理性与干预效果分析[J].临床医学,2018,38(7):96-99,102. [4]Kumar M,Prasad D,Yugal P,et al.Serum uric acid and target organ damage in essential hypertension at medicine department of gmc,bettiah,bihar[J].International Journal of Scientific Research,2020(2020):1-3. [5]张璐,郭燕亭.我院抗高血压药物的处方、药物使用情况及联合用药的合理性分析[J].临床医学研究与实践,2019,4(25):114-116. [6]陈卓.心内科老年高血压患者抗高血压药物用药的合理性与干预效果分析[J].中西医结合心血管病电子杂志,2020,8(4):25-26. [7]Anthony L,Rebecca R,Hyasinta J,et al.Herbal and Alternative Medicine Use in Tanzanian Adults Admitted with Hypertension-Related Diseases:A Mixed-Methods Study[J].International Journal of Hypertension,2017(2017):5692572. [8]袁进,刘贺萍,许百虹,等.基于国内外指南评价某院含抗高血压药物的处方联用的合理性[J].中国药房,2018,29(15):2114-2118. [9]姜淑华.心血管内科住院患者抗高血压药物使用合理性研究[J].黑龙江医药科学,2015,38(5):154-155. [10]孙雪卉.926例高血压患者药物治疗的合理性探讨[J].吉林医学,2012,33(17):3659-3660. [11]Zhang H,Li X,Huang J,et al.Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension:A Network Meta-Analysis[J].Medicine,2016,95(4):e2575. [12]刘艳杰.对某院2014年抗高血压药物处方评价及其合理性的分析[J].中国医药指南,2016,14(28):87-88. [13]葸风林,曹毅,刘桂兰,等.临床药师干预前后抗高血压药物临床使用合理性比较研究[J].甘肃医药,2015,34(6):454-456. [14]李爱娜.临床药学服务对高血压患者用药合理性及依从性的影响[J].中国现代药物应用,2020,14(2):212-213.

相似文献/References:

[1]颜 明,龚丽娜,王淑清.彩超在高血压患者肾动脉血流动力学检测中的应用分析[J].医学信息,2018,31(02):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
　YAN Ming,GONG Li-na,WANG Shu-qing.Application of Color Doppler Ultrasound in the Measurement of Renal Artery Hemodynamics in Patients with Hypertension[J].Medical Information,2018,31(11):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
　XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Medical Information,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(11):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]赵伟潭,朱祥路.焦虑在心血管内科的存在现况研究[J].医学信息,2018,31(05):53.[doi:10.3969/j.issn.1006-1959.2018.05.019]
　ZHAO Wei-tan,ZHU Xiang-lu.Research on the Current Status of Anxiety in Cardiovascular Medicine[J].Medical Information,2018,31(11):53.[doi:10.3969/j.issn.1006-1959.2018.05.019]
[5]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Medical Information,2018,31(11):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[6]董巧玲.健康教育对原发性高血压患者治疗效果的影响[J].医学信息,2018,31(09):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
　DONG Qiao-ling.Effect of Health Education on Treatment of Patients with Essential Hypertension[J].Medical Information,2018,31(11):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
[7]汤海霞,班 涛.大黄素与心血管疾病的研究[J].医学信息,2022,35(11):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
　TANG Hai-xia,BAN Tao.Research on Emodin and Cardiovascular Diseases[J].Medical Information,2022,35(11):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
[8]沈 正,王庆海.焦虑抑郁障碍与血压变异性研究[J].医学信息,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
　SHEN Zheng,WANG Qing-hai.Study on Anxiety and Depression Disorder and Blood Pressure Variability[J].Medical Information,2018,31(11):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
[9]左洪亮.苯磺酸左旋氨氯地平片治疗中老年患者 轻中度原发性高血压的疗效观察[J].医学信息,2018,31(16):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
　ZUO Hong-liang.Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients[J].Medical Information,2018,31(11):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
[10]袁 敏,周袁成.钙离子拮抗剂类降压药的临床应用与不良反应分析[J].医学信息,2018,31(17):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
　YUAN Min,ZHOU Yuan-cheng.Clinical Application and Adverse Reaction Analysis of Calcium Antagonist Antihypertensive Drugs[J].Medical Information,2018,31(11):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]

更新日期/Last Update: 1900-01-01